• Explore /
  • Poster
  • / Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.

Abstract Poster

Authors

null

Padmanee Sharma

MD Anderson Cancer Center, Houston, TX

Padmanee Sharma , Michael Krainer , Fred Saad , Daniel Castellano , Jens Bedke , Mariusz Kwiatkowski , Akash Patnaik , Giuseppe Procopio , Pawel Wiechno , Samith Thomas Kochuparambil , Christian Thomas , Jose Angel Arranz Arija , Steven L. McCune , Steinbjorn Hansen , Gedske Daugaard , Neha P. Amin , Yumeng Wang , Justin M. David , Russell Kent Pachynski

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02985957

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 22)

DOI

10.1200/JCO.2023.41.6_suppl.22

Abstract #

22

Poster Bd #

A7

Abstract Disclosures

Similar Posters

First Author: Shahneen Sandhu

First Author: Ovidio Fernandez Calvo

Poster

2015 Genitourinary Cancers Symposium

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Alice Clement-Zhao

First Author: Miguel Angel Climent Duran